Correction: Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial (Lancet Diabetes Endocrinol (2017) 5 (877–86) (S2213858717303091)(10.1016/S2213-8587(17)30309-1);Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 11, 2017, Pages 877-886

  Holman, Rury R ^a   Coleman, Ruth L ^a   Chan, Juliana C N ^b   Chiasson, Jean Louis ^c   Feng, Huimei ^a   Ge, Junbo ^d   Gerstein, Hertzel C ^e   Gray, Richard ^a   Huo, Yong ^f   Lang, Zhihui ^g   McMurray, John J ^h   Rydén, Lars ⁱ   Schröder, Stefan ^j   Sun, Yihong ^k   Theodorakis, Michael J ^a   Tendera, Michal ^l   Tucker, Lynne ^a   Tuomilehto, Jaakko ^m,n,o,p   Wei, Yidong ^q   Yang, Wenying ^k   Wang, Duolao ^r   Hu, Dayi ^s   Pan, Changyu ^t   Keenan, Joanne ^u   Milton, Joanne ^u   Doran, Zoe ^u   Bray, Chris ^u   Rouleau, Jean L ^u   Collier, Jane ^u   Pocock, Stuart ^u   Standl, Eberhard ^u   Swedberg, Karl ^u   Weng, Jianping ^u   Zhao, Dong ^u   Petrie, Mark C ^u   Connolly, Eugene ^u   Jhund, Pardeep ^u   MacDonald, Michael ^u   Myles, Rachel C ^u   Bai, Rong ^u   Li, Jing ^u   Liu, Zhaoping ^u   Liu, Zhenyu ^u   Peng, Dantao ^u   Tong, Qiguang ^u   Wang, Chunxue ^u   Yan, Xiaowei ^u   Zhang, Yuqing ^u   Zhou, Jingmin ^u   Sattar, Naveed ^u   Fisher, Miles ^u   Petrie, John R ^u   Bethel, M Angelyn ^u   Xu, Wen ^u   Hearn, Sarah ^u   Kappai, Anurag ^u   Su, Shu Yi ^u   Liyanage, Winitha ^u   Paul, Sanjoy ^u   Pozzi, Emanuela ^u   Ring, Arne ^u   Athwal, Rajbir ^u   Batra, Priyanka ^u   Ferch, Andrea ^u   Groves, Natasha ^u   Kennedy, Irene ^u   Nawalaniec, Olga ^u   Patel, Yash ^u   Roberts, Rachel ^u   Rush, Victoria ^u   Starrett, Jayne ^u   Tang, Jennifer ^u   Bi, Jing ^u   Jiang, Zhe ^u   Wei, Hua ^u   Wei, Xiaoshuai ^u   Zhang, Xuan ^u   Yin, Jun ^u   Sun, Yu ^u   Hu, Rong ^u   Liu, Yang ^u   Long, Jianjing ^u   Long, Yuefeng ^u   Qiao, Guofang ^u   Qiao, Haoyi ^u   Sun, Xiaochun ^u   Zhang, Yucheng ^u   Zhou, Jing ^u   Wang, Bangning ^u   Chen, Bin ^u   Deng, Lili ^u   Han, Xiaoning ^u   Hu, Taohong ^u   Hua, Qi ^u   Huo, Yanming ^u   Li, Hongmei ^u   Li, Hongwei ^u   Liu, Lihua ^u   Lu, Juming ^u   Ma, Changsheng ^u   Peng, Jianjun ^u   Pi, Lin ^u   Wang, Bin ^u,u   Wei, Guanglin ^u   Yang, Ming ^u   Zhang, Shuyang ^u   Zhang, Likun ^u   Zhao, Xia ^u   Zhou, Yujie ^u   Shi, Libin ^u   Wang, Mingsheng ^u   Wu, Lirong ^u   Han, Lei ^u   Liao, Ronghong ^u   Ran, Boli ^u   She, Qiang ^u   Tan, Jiancong ^u   Xia, Mei ^u   Yang, Chengming ^u   Chen, Lianglong ^u   Xiong, Shangquan ^u   Yu, Ling ^u   Pu, Xiaodong ^u   Wang, Yan ^u   Xie, Qiang ^u   Chen, Cibin ^u   Chen, Jiyan ^u   Dong, Yugang ^u   Wu, Zhaohui ^u   Yuan, Yong ^u   Zhou, Wanxing ^u   Zhou, Shuxian ^u   Chen, Xiaochao ^u   Wu, Chun ^u   Zhang, Aidong ^u   Li, Zicheng ^u   Lai, Shayi ^u   Yang, Jin ^u   Wei, Jinru ^u   Kuang, Riyu ^u   Zhao, Zilin ^u   Zhong, Guoqiang ^u   Cao, Xufen ^u   Hao, Yuming ^u   Liu, Gang ^u   Wang, Dongmei ^u   Fang, Hui ^u   Kong, Lingjun ^u   Li, Haitao ^u   Wang, Changqing ^u   Wang, Li'na ^u   Li, Xueqi ^u   Dong, Pingshuan ^u   Zhang, Shouyan ^u   Liu, Xincan ^u   Zhao, Yulan ^u   Liu, Hengliang ^u   Gu, Ye ^u   Liao, Yuhua ^u   Su, Xi ^u   Wang, Daowen ^u   Wang, Hairong ^u   Yang, Bo ^u   Guo, Ying ^u   Ouyang, Ding'an ^u   Yang, Tianlun ^u   Zhang, Yumin ^u   Han, Yajun ^u   Lin, Xuefeng ^u   Zhao, Ruiping ^u   Man, Ronghai ^u   Bian, Rongwen ^u   Biao, Xu ^u   Hasimu, Buaijiaer ^u   Jin, Hui ^u   Liu, Ping ^u   Yu, Jiangyi ^u   Zhang, Hang ^u   Xu, Chongli ^u   Guo, Yan ^u   Lv, Ke ^u   Tao, Yijia ^u   Xu, Xin ^u   Yang, Zhenyu ^u   Li, Dongye ^u   Qi, Chunmei ^u   Zhang, Guohui ^u   Gu, Xiang ^u   Hong, Lang ^u   Hu, Ling ^u   Li, Juxiang ^u   Yang, Ping ^u   Liu, Bin ^u   Wang, Gang ^u   Lin, Hailong ^u   Liu, Jun ^u   Zhang, Shuying ^u   Han, Ping ^u   Jin, Yuanzhe ^u   Li, Ling ^u   Li, Zhanquan ^u   Luan, Hong ^u   Song, Mei ^u   Xue, Li ^u   Hua, Yu ^u   Liu, Dongwu ^u   Yuan, Zuyi ^u   Ye, Jixian ^u   Gao, Feng ^u   Feng, Jinhua ^u   Wang, A'li ^u   Ye, Shengming ^u   Li, Xiaoyan ^u   Su, Guohai ^u   Zhang, Shufang ^u   Hou, Zishan ^u   Jiang, Wenbin ^u   Zhou, Changyong ^u   Wang, Yanping ^u   Qi, Wenbo ^u   Bao, Xiaomei ^u   Feng, Bo ^u   Gong, Hui ^u   Gu, Shuiming ^u   Gu, Mingjun ^u   Guo, Xingui ^u   He, Ben ^u   Huang, Ying ^u   Jiang, Jinfa ^u   Jiang, Yifeng ^u   Jin, Huigen ^u   Li, Yuehua ^u   Liu, Qiliang ^u   Lu, Guoping ^u   Miao, Peizhi ^u   Qin, Yongwen ^u   Wang, Yuanming ^u   Wu, Shiyao ^u   Xu, Yawei ^u   Ma, Jin ^u   Chen, Xiaoping ^u   Liu, Xiumin ^u   Tang, Jianing ^u   Wang, Jingping ^u   Tao, Jianhong ^u   Zhang, Jun ^u   Zhang, Tingjie ^u   Li, Decai ^u   Du, Xinping ^u   Jiang, Tiemin ^u   Lin, Jingna ^u   Lu, Chengzhi ^u   Ma, Hongjun ^u   Gao, Bo ^u   Guo, Xukun ^u   Li, Tong ^u   Zheng, Shaoxiong ^u   Li, Zhongcheng ^u   Zhao, Shuwu ^u   Qiu, Qiang ^u   Li, Kaili ^u   Liu, Junming ^u   Tang, Baopeng ^u   Yuan, Zhanjun ^u   Zhou, Jianhua ^u   Bai, Wenwei ^u   Guo, Tao ^u   Zhang, Ge ^u   Zhang, Hong ^u   Hao, Yinglu ^u   Fu, Guosheng ^u   Tang, Lijiang ^u   Chen, Jialun ^u   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d FUDAN UNIVERSITY   (China)

^e HAMILTON HEALTH SCIENCES   (Canada)

^f PEKING UNIVERSITY FIRST HOSPITAL   (China)

^g Bayer Healthcare Company Ltd   (China)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j BAYER AG   (Germany)

^k Clinical Research Institute of China   (China)

^l MEDICAL UNIVERSITY OF SILESIA   (Poland)

^m DASMAN DIABETES INSTITUTE   (Kuwait)

ⁿ DANUBE UNIVERSITY KREMS   (Austria)

^o NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^p KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^q TONGJI UNIVERSITY   (China)

^r LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^s PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^t CHINESE PLA GENERAL HOSPITAL   (China)

^u NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; PLACEBO; ANTIDIABETIC AGENT; GLYCOSIDASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT WITHDRAWAL; UNSTABLE ANGINA PECTORIS; AGED; CARDIOVASCULAR DISEASE; COMPLICATION; CORONARY ARTERY DISEASE; GLUCOSE INTOLERANCE; KAPLAN MEIER METHOD; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME;

ACARBOSE; AGED; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE INTOLERANCE; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 85029223251     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30335-2     Document Type: Erratum

References (25)

1. George, A, Bhatia, RT, Buchanan, GL, et al. Impaired glucose tolerance or newly diagnosed diabetes mellitus diagnosed during admission adversely affects prognosis after myocardial infarction: an observational study. PLoS One, 10, 2015, e0142045.
2. Ritsinger, V, Tanoglidi, E, Malmberg, K, et al. Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort. Diab Vasc Dis Res 12 (2015), 23–32.
3. Tominaga, M, Eguchi, H, Manaka, H, Igarashi, K, Kato, T, Sekikawa, A, Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (1999), 920–924.
4. Edelstein, SL, Knowler, WC, Bain, RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46 (1997), 701–710.
5. Hu, D-Y, Pan, C-Y, Yu, J-M, for the China Heart Survey Group. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 27 (2006), 2573–2579.
6. Chiasson, J-L, Josse, RG, Gomis, R, Hanefield, M, Karasik, A, Laakso, M, for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002), 2072–2077.
7. Chiasson, J-L, Josse, RG, Gomis, R, Hanefiex, Karasik, A, Laakso, M, for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in subjects with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 290 (2003), 486–494.
8. Hanefeld, M, Chiasson, JL, Koehler, C, Henkel, E, Schaper, F, Temelkova-Kurktschiev, T, Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35 (2004), 1073–1078.
9. Hanefeld, M, Cagatay, T, Petrowitsch, D, Neuser, D, Petzinna, D, Rupp, M, Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25 (2004), 10–16.
10. Standl, E, Theodorakis, MJ, Erbach, M, Erbach, M, Schnell, O, Tuomilehto, J, On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol, 13, 2014, 81.
11. Holman, RR, Bethel, MA, Chan, JCN, et al., for the ACE Study Group. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am Heart J 168 (2014), 23–29.
12. Holman, R, Nicholls, M, The University of Oxford Diabetes Trials Unit. Eur Heart J 36 (2015), 1706–1707.
13. Theodorakis, MJ, Coleman, RL, Feng, H, et al. Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. Am Heart J, 2017 published online Sept 8. DOI:10.1016/j.ahj.2017.09.001.
14. Ma, YC, Zuo, L, Chen, JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17 (2006), 2937–2944.
15. McMurray, JJV, Gerstein, HC, Holman, RR, Pfeffer, MA, Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 (2014), 843–851.
16. Zheng, M-Y, Yang, J-H, Shan, C-Y, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol, 12, 2013, 73.
17. Sokos, GG, Nikolaidis, LA, Mankad, S, Elahi, D, Shannon, RP, Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006), 694–699.
18. Sawicki, PT, Kaiser, T, Response to Chiasson et al: acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 47 (2004), 976–977.
19. Holman, RR, Cull, CA, Turner, RC, for the UKPDS Study Group. A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycamic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 22 (1999), 960–964.
20. Asakura, M, Kim, J, Asanuma, H, et al. Does treatment of impaired glucose tolerance improve cardiovascular outcomes in patients with previous myocardial infarction?. Cardiovasc Drugs Ther, 2017 published online Aug 4. DOI:10.1007/s10557-017-6740-3.
21. NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362 (2010), 1463–1476.
22. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375 (2010), 2215–2222.
23. Li, G, Zhang, P, Wang, J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2 (2014), 474–480.
24. Saad, MF, Knowler, WC, Pettitt, DJ, Nelson, RG, Mott, DM, Bennett, PH, The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319 (1988), 1500–1506.
25. Bethel, MA, Holman, R, Haffner, SM, et al. Determining the most appropriate components for a composite clinical trial outcome. Am Heart J 156 (2008), 633–640.